New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 3, 2014
06:33 EDTCLVS, FMIFoundation Medicine and Clovis Oncology partner for cancer diagnostic
Foundation Medicine (FMI) and Clovis Oncology (CLVS) are expanding their ongoing collaboration to incorporate a coordinated regulatory strategy for the development of a novel Premarket Approval companion diagnostic test. This test is designed for use by physicians to identify patients most likely to respond to rucaparib, Clovis’ poly polymerase inhibitor currently the subject of Phase 2 and Phase 3 clinical trials in patients with ovarian cancer. This companion diagnostic is being developed in parallel with the clinical development of rucaparib to facilitate an FDA submission of the PMA for the companion diagnostic concurrent with the New Drug Application for rucaparib.
News For FMI;CLVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
13:10 EDTCLVSOppenheimer reports 5.23% passive stake in Clovis
January 16, 2015
16:36 EDTFMIMarket finishes week lower on continued oil, global growth worries
Subscribe for More Information
10:01 EDTFMIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:51 EDTFMIFoundation Medicine downgraded to Market Perform from Outperform at Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use